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Nine episodes of CPD-associated peritonitis with vancomycin resistant
enterococci. Nine episodes of chronic peritoneal dialysis (CPD)-associated
peritonitis with vancomycin resistant enterococci (VRE) were described
betveen November 1993 and February 1996 in our dialysis unit. During
the time period, 216 patients were treated for 227 episodes of peritonitis.
Of the patients developing peritonitis with VRE the mean age SD was
56.3 9.7 years. There were 5 females, 4 males, 5 Caucasians and 4
African-Americans. Diabetes mellitus, cardiovascular disease and gastro-
intestinal disease were present in 7, 8 and 7 of the 9 patients with VRE
peritonitis, respectively. Patients were maintained on CPD therapy for an
average of 29.9 19.2 patient months before developing VRE peritonitis.
The prior rate of CPD associated peritonitis in the patients developing
VRE peritonitis was significantly higher than the rate noted in the CPD
patients not developing peritonitis with VRE (1 episode in 6.3 patient
months vs. 1 episode in 12.5 patient months, P < 0.05). All 9 patients had
used vancomycin in the six months prior to the development of VRE
peritonitis and 78% had used a cephalosporin. The antimicrobial therapy
used to eradicate peritonitis with VRE varied among the 9 patients with
chioramphenicol used in 4 patients. The Tenckhoff catheter was removed
in 6 of the 9 patients and was successfully reinserted in one patient. The
catheter was not removed in 3 patients and 2 of these patients expired.
Five of the 9 patients expired while being treated for VRE, 2 transferred
to hemodialysis and 2 continued CPD therapy. VRE peritonitis is a major
concern for patients maintained on CPD therapy. Future studies are
needed with case controls to determine the significance of prior vanco-
mycin and cephalosporin therapy, fecal VRE carriage and certain demo-
graphic data on the acquisition of VRE peritonitis. Furthermore, the
optimal therapy and outcome may be better clarified through such a
review.
Continuous peritoneal dialysis (CPD) associated peritonitis
remains a major complication of CPD therapy. Although there
have been several advances in CPD technique that have resulted
in a decrease in the peritonitis rate, peritonitis remains the leading
cause of patient dropout [1]. Recently, the emergence of CPD
associated peritonitis secondary to vancomycin resistant entero-
cocci (VRE) has presented yet another challenge to the manage-
ment of peritonitis [2, 3].
Nosocomial infection secondary to VRE in the general medical
population has increased from 0.3% to 7,9% between 1989 and
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1993 [4]. VRE poses major infectious disease problems because it
is difficult to treat due to limited effective antibiotics and because
there is a threat of transfer of this resistance to other gram-
positive organisms including Staphylococcus aureus. This has lead
to the development of the Hospital Infection Control Practices
Advisory Committee (HICPAC) of the Centers for Disease
Control (CDC), which has now developed detailed guidelines to
limit the spread of this organism. Specifically, this committee
discourages the use of vancomycin for "routine prophylaxis for
patients on continuous ambulatory peritoneal dialysis or hemodi-
alysis" and for "treatment (chosen for dosing convenience) of
infections caused by beta-lactam-sensitive gram-positive microor-
ganisms in patients who have renal failure" [5].
The Ad Hoc Committee on Peritonitis Management suggests
that the empirical antibiotic therapy of CPD associated peritonitis
should consist of both vancomycin and gram-negative coverage
[6]. Since the publication of the recommendations of the Ad Hoc
Committee in 1993 a better understanding of the epidemiology of
infection with VRE among the general medical population has
developed. There are data among the general medical population
suggesting that prior vancomycin and/or multiantimicrobial expo-
sure may predispose patients to the development of infection with
VRE [7, 8]. General medical patients with severe underlying
disease are also thought to be inclined to infection with VRE [9,
10]. Several reports link VRE stool carriage with VRE infection
[11, 12].
Thus, we felt it was important to describe our experience with
CPD-associated peritonitis with VRE.
Methods
We retrospectively reviewed the peritonitis records of the
patients maintained on CPD therapy in our unit between Novem-
ber 1993 and February 1996 to identify patients developing CPD
associated peritonitis with enterococcal species. The organization
and structure of our CPD unit has been previously described [13].
All patients had a double cuff silastic Tenckhoff catheter inserted
by standard surgical techniques as previously described [13].
Peritonitis was defined by the presence of a cloudy dialysis
effluent with greater than 100 white blood cells/mm3 and a white
blood cell differential count of greater than 50% polymorphonu-
clear cells as previously described [13]. The peritoneal effluent was
cultured by obtaining a 100 cc aliquot of effluent and centrifuging
this specimen. The sediment was then plated on blood chocolate
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agar, anaerobic blood agar and CNA plates and incubated for 72
hours [13]. Enterococcal colonies were identified by gram stain,
catalase and PYR tests. Enterococcal species identification and
rapid minimum inhibitory concentration (MIC) testing were done
on the Baxter Walkaway-96. The enterococcal isolates with an
MIC for vancomycin of greater than 16 sg were determined to be
vancomycin resistant enterococci.
The charts of the CPD patients developing peritonitis with
VRE were reviewed retrospectively for: (a) basic demographic
data including age, race, gender and etiology of end-stage renal
disease (ESRD), (b) the species of each enterococcal isolate, (c)
the setting of presumed acquisition of VRE peritonitis, (d) the
time, in months, maintained on CPD therapy until developing
VRE peritonitis, (e) the peritonitis rate of each patient develop-
ing VRE peritonitis, (f) the use of antimicrobial therapy at the
presentation of VRE peritonitis and in the preceding one, three
and six months, (g) presence of active gastrointestinal disease at
the time of development of VRE peritonitis and (h) the presence
of VRE in the feces. The treatment modalities and outcome
measures including the removal of the Tenckhoff catheter were
also reviewed retrospectively.
The peritonitis rate was expressed as occurrences per patient
months and was calculated by dividing the total number of patient
months by the total number of episodes of peritonitis. The
peritonitis rate refers to the cummulative rate of all episodes of
peritonitis of the patients developing VRE peritonitis. The mean
serum albumin concentration was calculated by averaging three
serum albumin concentrations obtained prior to the development
of VRE peritonitis.
The presence of VRE in the stool was determined by placing
fecal material on campylobacter blood agar plates containing 10
jsg of vancomycin as described by Edberg et al [14]. After an
incubation period of 24 hours enterococcal isolates with either
VanA or VanB resistance were determined to be present if
growth was observed.
Results
Between November 1993 and February 1996 216 patients were
maintained on CPD therapy in our unit. A total of 227episodes of
CPD associated peritonitis occurred during this time period and
24 of these episodes were secondary to enterococcal organisms.
VRE was identified in 9 of these episodcs and thus accounted for
3 7.5% of the episodes of enterococcal peritonitis and for 4% of all
episodes of peritonitis.
Demographics
The nine CPD patients developing VRE peritonitis had a mean
age SD of 56.3 9.7 years with a range of 39 to 75 years. Five
of the patients were female and four were male. There were five
Caucasians and four African-Americans. The cause of ESRD was
diabetes mellitus in seven patients (78%), polycystic kidney
disease in one patient (11%) and focal segmental glomeruloscie-
rosis in one patient (11%). Patients were maintained on CPD
therapy for an average of 29.9 19.2 months with a range of nine
to 69 months before developing VRE peritonitis.
Cardiovascular disease was documented in eight of the nine
patients (89%) and gastrointestinal disease was noted in seven of
the nine patients (78%) developing VRE peritonitis. Gastrointes-
tinal disease included chronic diarrhea in five patients, gallstones
in two patients, perforated sigmoid diverticulum in one and
Table 1. Antecedant antibiotic use in the 9 patients developing
VRE peritonitis
—
Time period Vancomyein use Cephalosporin USea
At time of VRE episode 5 (56%) 3 (33%)
During the prior 3 months 8 (89%) 5 (56%)
During the prior 6 months 9 (100%) 7 (78%)
—
a Includes all generations of cephalosporins
autoimmune cirrhosis in one. Two patients had two active gastro-
intestinal diseases.
Microbiology
Ten enterococcal organisms were identified in the nine epi-
sodes of VRE peritonitis; one patient developed infection with
two different VRE isolates. The specific organisms included
Enterococcus faecium in four episodes, Enterococcus faecalis in
one and Enterococcus avium in one. Enterococci were not speci-
ated in four episodes.
Setting
Five of the nine patients developed VRE peritonitis during a
hospitalization or within 14 days of discharge from an acute care
hospital. The remaining four patients developed VRE peritonitis
within the community. These latter four patients had a hospital
stay two, three, nine and ten months before developing VRE
peritonitis.
Peritonitis history
There were 43 episodes of CPD-associated peritonitis in 269
patient months identified among the nine patients prior to the
development of VRE peritonitis. Therefore, the overall rate of
peritonitis was one episode in 6.3 patient months, which was
significantly higher than the overall rate of peritonitis for the
remaining CPD population not developing VRE peritonitis, one
episode in 12.5 patient months (P < 0.05).
Antecedent antibiotic use
The use of antimicrobial therapy at the time of and three
months and six months prior to the development of VRE perito-
nitis is outlined in Table 1. All nine patients used vancomycin and
seven patients (78%) used a eephalosporin in the six months prior
to the development of VRE peritonitis. Other antimicrobial
therapies used in the six months prior to VRE peritonitis included
fioroquinolones in four patients, penicillins in two patients, ami-
noglycosides in five patients and amphotericin in one patient.
Antimicrobial therapy was used to treat 16 episodes of CPD-
associated peritonitis. Antibiotics were also used to treat entero-
coccal sepsis (non-VRE) in one patient, an upper respiratory
infection in one patient, infected foot ulcers in two patients,
prophylactic therapy in one patient and hepatic encephalopathy in
one patient.
I/RE stool carriage
Four of the nine patients developing VRE peritonitis had stool
specimens screened for the presence of VRE. Of these four
patients, two had evidence of VRE in the stool prior to the
development of VRE peritonitis.
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Table 2. Treatment and outcome of VRE peritonitis
Tenckhoff
Patient Treatment catheter Outcome






SR. Chioramphenicol IV Removed Expired
A.K. Cefazolin IP Not removed Expired
J.M. Vancomycin and
Ceftazidime
Not removed Remained on CPD




















The antimicrobial therapy, removal of the Tenckhoff catheter
and outcome of each episode of VRE peritonitis is outlined in
Table 2.
The antimicrobial therapy used to eradicate infection with VRE
varied among the nine patients. Chloramphenicol therapy was
used in four patients (Table 2). In one patient cefazolin was used
prior to the diagnosis of the VRE. The peritoneal fluid cleared
and all subsequent cultures were negative for VRE. One patient
was treated with vancomycin and ceftazidime; the VRE was not
identified until seven days after the presentation with cloudy fluid
and initiation of antimicrobial therapy. The peritoneal fluid
gradually cleared with this antimicrobial regimen. One patient
expired at the time of diagnosis of VRE peritonitis and therefore
was not able to receive treatment.
The Tenckhoff catheter was removed in six of the nine patients
in attempt to eradicate the infection. Of the six patients who had
the catheter removed three had the catheter removed within 24
hours of the diagnosis of VRE peritonitis. The remaining three
patients did not clear the peritoneal fluid with antimicrobial
therapy alone and the catheters were removed 5, 8 and 11 days
after the diagnosis of VRE peritonitis. Of the patients who had
the Tenckhoff catheter removed only one patient had the Tenck-
hoff catheter successfully reinserted.
The Tenckhoff catheter was not removed in three patients; two
patients expired; one patient clinically improved with antimicro-
bial therapy alone and had subsequent peritoneal fluid cultures
negative for VRE.
Five of the nine patients (56%) developing VRE peritonitis
expired while being treated. The cause of death was related to
cardiovascular disease in four patients and septic shock in one.
Two patients (22%) were able to continue CPD therapy. Two
patients (22%) were permanently transferred to hemodialysis;
one patient had a colostomy following perforation of a sigmoid
diverticulum and one patient had persistent VRE stool carriage,
hepatic encephalopathy and repeated demonstration of poor CPD
technique.
Discussion
Since 1989 the percentage of nosocomial infection with VRE
among the general medical population has increased to 7.9%
from 0.3% of all enterococcal isolates. Prior to the present paper
four episodes of CPD-associated peritonitis with VRE have been
described [2, 3]. We now report nine additional episodes of VRE
peritonitis.
Le Clerq et al in 1988 were the first to describe inducible high
level resistance to vancomycin among clinical isolates of entero-
cocci [51. Since his description several reports have described the
emergence of VRE among the general medical population as a
serious and rapidly spreading pathogen [9, 10, 15—191. Morris et al
concluded that VRE was a significant cause of morbidity and
mortality most notably in seriously ill patients [9]. Frieden et al via
molecular analysis of VRE isolates from a large series of patients
suggested that a "highly mobile genetic element" termed a
transposon within the VRE was responsible for the endemic
spread of vancomycin resistance [19]. Furthermore, of major
epidemiological concern is the observation that vancomycin resis-
tance among enterococcal isolates can be transferred in vitro to
other gram-positive organisms including Staphylococci [201. There
are already three episodes of CPD associated peritonitis with
coagulase-negative Staphylococci resistant to vancomycin re-
ported in the literature [2, 211.
Many enterococcal species have been cited to be responsible for
VRE infection among the general medical population with En-
terococcus faecium accounting for 86% to 96% of all vancomycin
resistant enterococcal isolates in some reports [9, 19]. Other
isolates reported have included Enterococcus faecalis, Enterococ-
cus avium and Enterococcus gallinarum [2, 9, 19]. Four of the nine
episodes of VRE peritonitis were secondary to Enterococcus
faecium in our study. Four enterococcal isolates were not speei-
ated.
In most reports among the general medical population VRE
has been documented to have been acquired as a nosoeomial
infection [7, 16, 19, 221. For example, Frieden et al noted that 98%
of the VRE infections among the general medical population
were acquired nosocomially [19]. While all nine of our patients
had hospital stays in the twelve months prior to the development
of VRE peritonitis, only five patients (56%) developed VRE
peritonitis as a true nosocomial infection. It is not clear if the
other four patients were exposed to VRE during a prior hospital
stay and became colonized and subsequently developed infection.
Alternatively, the VRE may have been acquired in the community
setting.
Could there be any factors which may heighten the concern for
the development of VRE peritonitis? Our study of nine patients is
too small to clearly identify the risk factors for the development of
VRE peritonitis. It is noteworthy, however, that in the general
medical population certain patient groups may be predisposed to
infection with VRE such as immunocompromised patients and
patients with increased severity of underlying disease [9, 22].
Patients with prior vancomycin and cephalosporin use, particu-
larly broad spectrum third generation cephalosporins, have also
been described amongst patients developing VRE infection in the
general medical population [7, 8]. Vancomycin use has been
suggested to eradicate vancomycin sensitive bowel flora and thus
select for the growth of vancomycin resistant organisms [10, 191.
Additionally, since enterococci are enteric organisms traditionally
resistant to penicillins and beta lactamases use of broad spectrum
cephalosporin antimicrobial therapy could, in turn, select more
resistant organisms [11, 15]. One may speculate that concurrent
vancomycin therapy in this setting helped select vancomycin
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resistant organisms. In the CPD population frequent CPD-asso-
ciated peritonitis has also been suggested to predispose patients to
the development of VRE infection [2].
Vancomycin and cephalosporin therapy, particularly the third
generation ceftazidime, have without doubt been very effective in
the management of CPD-associated peritonitis and are currently
the mainstay therapy of CPD-associated peritonitis [61. Proper
antimicrobial therapy for CPD-associated peritonitis has included
appropriate coverage for the most common CPD peritonitis
pathogens, coagulase negative Staphylococci and Staphylococcus
aureus. At our institution approximately 55% of our coagulase
negative Staphylococci are resistant to cephalosporin therapy in
addition to most alternative antimicrobial therapies thus making
vancomycin use necessary. However, with the increasing threat of
VRE infection do we need to modify the current approach to
CPD-associated peritonitis? Future studies comparing CPD pa-
tients developing VRE peritonitis with case-controls are needed
to respond to the questions of limiting vancomycin and/or ceph-
alosporin use.
Fecal cultures for VRE have been adopted by most hospitals to
identify patients who may be colonized with VRE. Jordens, Bates
and Griffiths were able to demonstrate in a large series of fecal
specimens that the highest level of fecal carriage was among
patients with renal disease [11]. It has been well described that
colonization of VRE in the feces may lead to clinical infection in
susceptible hosts [12]. Only four of our nine patients were tested
for fecal VRE and two of the four patients were known to be
colonized with VRE in the feces prior to the development of VRE
peritonitis.
The institution of efficacious antimicrobial therapy is important
in the treatment of VRE infection. However, what constitutes
appropriate antimicrobial therapy of VRE peritonitis is uncertain.
Enterococci have traditionally been resistant to a wide variety of
antimicrobial therapies including aminoglycosides, cephalospo-
rins and penicillins and more recently glycopeptides, making
therapy of enterococcal infection challenging. Chloramphenicol,
although bacteriostatic in nature, has been suggested to be
effective in the treatment of VRE infection among the general
medical population [23]. Quinupristin/dalfopristin has been used
with some success with and without Tenckhoff catheter removal in
one report of three patients with VRE peritonitis [3]. This
experimental medication not yet approved by the FDA may
represent a therapeutic solution in the treatment of VRE perito-
nitis. The limited experience with VRE peritonitis does not permit
an adequate definition of optimal therapy, that is, which antibiotic
to use and whether the peritoneal catheter must be removed.
Future reports of VRE peritonitis may help clarify optimal
therapy for VRE peritonitis.
The outcome of VRE peritonitis was poor in regard to both
patient mortality and continuation of CPD therapy. Five of the
nine patients expired and only two of the nine patients were able
to continue CPD therapy. This impressive mortality noted among
our patients developing VRE peritonitis was not a surprise as
several reports among the general medical population have
documented a striking mortality associated with VRE infection [7,
9, 19, 22]. It is noteworthy in our study the patients had significant
comorbid diseases as seven of nine patients were diabetic, eight
had underlying cardiovascular disease and seven had evidence of
preexistent gastrointestinal disease. It is impossible to determine
to what extent each of these comorbid diseases contributed to
each patient's demise.
In conclusion, VRE peritonitis is a major concern for patients
maintained on CPD therapy. Further studies are necessary with
case-controls to determine whether vancomycin and cephalospo-
rin therapy predispose patients to the development of VRE
infection. Once such studies are performed the current approach
to the treatment of CPD-associated peritonitis may need to be
modified for a more prudent use of antimicrobial therapy. Future
studies are needed to examine the significance of fecal VRE
carriage as a risk for the development of VRE peritonitis. Current
antimicrobial therapy for VRE peritonitis appears to be inade-
quate. Finally, the outcome noted among our nine patients was
very poor. Although there was a high frequency of comorbid
disease amongst our patients, it is not clear whether the episode of
VRE peritonitis or the presence of the comorbid disease was the
cause of the high mortality. Continued experience with VRE
peritonitis should provide additional insight.
Reprint requests to Dr. Frederic Finkeistein, MD., New Haven CPD, 136
Sherman Avenue, New Haven, Connecticut 06511, USA.
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